AbbVie announced that it has received marketing approval in Japan for Aquipta tablets (atogepant), a calcitonin gene-related peptide (CGRP) receptor antagonist, for the prevention of migraine attacks in… read more.
Lundbeck announced the acceptance of its new drug application (NDA) for Vyepti (eptinezumab) by the Ministry of Health, Labor and Welfare (MHLW) in Japan. The submission reflects the… read more.
Efforts to promote safer opioid prescribing in Canada appear to be having an effect, as new research in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250670 shows a decrease in opioid dispensing between 2018 and… read more.
New research from The University of Texas at Arlington shows that differences in state welfare policies are linked to rising arthritis-related joint pain across much of the U.S…. read more.
When older adults living in nursing homes are prescribed the pain medicine tramadol alongside certain antidepressants, their risk of seizures may go up, according to a study published… read more.
Asking people how much money they would accept to experience pain again can provide a more accurate and comparable measure of pain levels than the familiar 1–10 scale,… read more.
Temporomandibular disorder (TMD) limits jaw function and is so painful that it lessens the quality of life. Botulinum toxin—also known as botox—is emerging as an effective treatment option,… read more.
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.
The use of powerful synthetic opioids, such as sufentanil and remifentanil, during surgery is linked to a subsequent poor ‘pain experience’—a composite of emotional, cognitive, and physical aspects… read more.
A multidisciplinary team of University of Cincinnati Cancer Center researchers is leading a new clinical trial aimed to optimize pain management and reduce the need for opioids after… read more.
Axsome Therapeutics, Inc. announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. Symbravo represents a novel… read more.
Atogepant, an oral drug approved to prevent migraine, appears to also alleviate migraine symptoms early after onset has begun. The findings were reported on December 23, 2024 in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
